The Shotlee Journal
Browse Shotlee articles about GLP-1 Medications.
Showing 9 / 939 GLP-1 Medications articles
Midlife weight gain is hitting millennial stars hard, but many are turning to Ozempic and other GLP-1s for help. Celebrities including Amy Schumer, Golnesa 'GG' Gharachedaghi, and Serena Williams have openly admitted to using these medications, sharing their triumphs, side effects, and transformations. Discover their stories and the science behind these popular drugs.
New research uncovers potential effects of SNAC—the hidden ingredient enabling Ozempic and Wegovy tablets—on gut health. In a 21-day animal study, repeated exposure led to shifts in harmful gut bacteria, elevated inflammation, and depleted cognitive proteins. While not proving harm in humans, findings urge caution as oral semaglutide use surges.
Millionaire Gemma Collins is flogging her once-worn clothes on Vinted after shedding 3 stone with Mounjaro injections. From size 26 to 20, the TOWIE star shares how the jabs curbed her food obsession. But a gallbladder scare paused her treatment—here's her full story.
Tess Holliday, a prominent body positivity advocate, shared her shocking experience of being denied life insurance solely because she weighs over 300 pounds at 5 foot 3, despite no pre-existing conditions or medications. Her story highlights deep-rooted fatphobia in the insurance and medical systems. Amid GLP-1 drugs like Ozempic promoting thin ideals, she relaunches #EffYourBeautyStandards to fight back.
A safety alert from the MHRA warns of counterfeit Mounjaro pens distributed to the public, posing risks due to unknown sterility despite containing tirzepatide. Five affected pens were supplied through a Birmingham pharmacy, with defects like detaching dose knobs reported. Check your batch number and stop use immediately if impacted.
Abbott has tied up with Novo Nordisk India to commercialize Extensior, the second brand of semaglutide injection following Ozempic's launch. This move positions Abbott as the second firm with sole distribution rights for Novo's semaglutide portfolio in India, after Emcure Pharma. With demand surging and generics on the horizon, here's what it means for patients.
Novo Nordisk's Ozempic pioneered the GLP-1 revolution, tripling sales to 309 billion DKK in eight years. Yet shares have cratered 60% due to Eli Lilly's Mounjaro gains, trial disappointments, and looming generics. Discover the booming market's challenges and opportunities.
Abbott is now marketing Extensior, a second brand of Novo Nordisk's Ozempic, for type 2 diabetes management in India. This partnership comes as the semaglutide patent nears expiry, potentially lowering prices. With proven benefits in HbA1c control, weight loss, and cardiovascular risk reduction, it expands access in a country with over 100 million diabetes cases.
With nearly 100 million Indians overweight or obese, Eli Lilly is ramping up access to its game-changing drug Mounjaro across the country. President Winslow Tucker emphasizes responsible use under medical supervision amid rising demand for GLP-1 therapies. This move signals a shift in tackling obesity as a serious disease linked to heart complications.
